MA34106B1 - Combinaison de composés organiques - Google Patents

Combinaison de composés organiques

Info

Publication number
MA34106B1
MA34106B1 MA35274A MA35274A MA34106B1 MA 34106 B1 MA34106 B1 MA 34106B1 MA 35274 A MA35274 A MA 35274A MA 35274 A MA35274 A MA 35274A MA 34106 B1 MA34106 B1 MA 34106B1
Authority
MA
Morocco
Prior art keywords
combination
organic compounds
pharmaceutical combination
benzimidazol
methylpiperazin
Prior art date
Application number
MA35274A
Other languages
Arabic (ar)
English (en)
Inventor
Diana Graus-Porta
Michael Shi
Dean Brent Evans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44009923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34106(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34106B1 publication Critical patent/MA34106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique comprenant de la 4-amino-5-fluoro-3-[6-(4-méthylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one et au moins un inhibiteur de mtor, et la combinaison pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie proliférative.
MA35274A 2010-04-16 2011-04-14 Combinaison de composés organiques MA34106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32501810P 2010-04-16 2010-04-16
PCT/EP2011/055908 WO2011128405A1 (fr) 2010-04-16 2011-04-14 Combinaison de composés organiques

Publications (1)

Publication Number Publication Date
MA34106B1 true MA34106B1 (fr) 2013-03-05

Family

ID=44009923

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35274A MA34106B1 (fr) 2010-04-16 2011-04-14 Combinaison de composés organiques

Country Status (19)

Country Link
US (1) US20130035343A1 (fr)
EP (1) EP2558082A1 (fr)
JP (1) JP2013525292A (fr)
KR (1) KR20130092412A (fr)
CN (1) CN102834094B (fr)
AU (1) AU2011240001B2 (fr)
BR (1) BR112012026285A2 (fr)
CA (1) CA2795089A1 (fr)
CL (1) CL2012002858A1 (fr)
IL (1) IL222313A0 (fr)
MA (1) MA34106B1 (fr)
MX (1) MX2012012058A (fr)
NZ (1) NZ602807A (fr)
PH (1) PH12012501977A1 (fr)
RU (1) RU2012148706A (fr)
SG (1) SG184311A1 (fr)
TN (1) TN2012000477A1 (fr)
WO (1) WO2011128405A1 (fr)
ZA (1) ZA201207234B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
MX2013013437A (es) * 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
GB201217890D0 (en) * 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
WO2014160328A1 (fr) * 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1995014023A1 (fr) 1993-11-19 1995-05-26 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
CA2496164C (fr) 2002-08-23 2010-11-09 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
TWI347940B (en) * 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
EP2168603A1 (fr) * 2003-11-14 2010-03-31 GenVec, Inc. Posologie thérapeutique pour le traitement du cancer
WO2006124413A2 (fr) * 2005-05-13 2006-11-23 Novartis Ag Procedes pour traiter un cancer pharmacoresistant
EP2270000B1 (fr) 2005-05-23 2015-07-29 Novartis AG Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one
CA2680161A1 (fr) * 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Composition pharmaceutique
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Also Published As

Publication number Publication date
SG184311A1 (en) 2012-11-29
CA2795089A1 (fr) 2011-10-20
PH12012501977A1 (en) 2013-01-07
CL2012002858A1 (es) 2013-01-25
MX2012012058A (es) 2012-11-22
CN102834094B (zh) 2015-05-06
AU2011240001B2 (en) 2014-05-08
CN102834094A (zh) 2012-12-19
US20130035343A1 (en) 2013-02-07
WO2011128405A1 (fr) 2011-10-20
AU2011240001A1 (en) 2012-11-08
RU2012148706A (ru) 2014-05-27
NZ602807A (en) 2014-02-28
EP2558082A1 (fr) 2013-02-20
JP2013525292A (ja) 2013-06-20
KR20130092412A (ko) 2013-08-20
ZA201207234B (en) 2013-05-29
BR112012026285A2 (pt) 2016-07-12
IL222313A0 (en) 2012-12-31
TN2012000477A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA40290A1 (fr) Agents immunorégulateurs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
EP2857007A4 (fr) Composition pharmaceutique contenant un dérivé de verbénone pour le traitement ou la prévention d'une maladie neurodégénérative
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
BR112012026285A2 (pt) combinação de compostos orgânicos